INVESTORS & MEDIA
News Release
Regeneron and The University of Texas Southwestern Medical Center at Dallas Enter Into a Strategic VelocImmune((R) )Agreement to Discover Human Monoclonal Antibodies
Under the agreement, scientists at
UT
"VelocImmune is a unique antibody platform
that allows researchers with limited antibody-production resources to
create high affinity, well expressed, fully human antibodies in their
own laboratories," said
About VelocImmune and the Regeneron VelociSuite of Technologies
Regeneron has developed and validated a group of novel technology
platforms, known as the VelociSuite™ of
technologies, to improve its ability to develop new product candidates. VelociGene®
and VelociMouse® are designed to aid in
the identification of specific genes of therapeutic interest for a
particular disease or cell type and validate targets through
high-throughput production of mammalian models. VelocImmune®
increases the speed and efficiency of fully human monoclonal antibody
development and is currently being used to generate antibodies to
address clinically relevant targets of therapeutic interest. The VelocImmune
mouse, unlike other human-antibody-producing mice, mounts a robust
immune response that is virtually indistinguishable from that of a wild
type mouse, resulting in a reliable and efficient platform for
discovering fully human monoclonal antibodies.
Two antibodies developed using VelocImmune® are in Phase 1 clinical trials. These are an antibody to Interleukin-6R (IL-6R) for the treatment of rheumatoid arthritis and an antibody to Nerve Growth Factor (NGF) for the treatment of pain.
Additionally, an Investigational New Drug (IND) Application has been filed for a Phase 1 study of a third antibody developed using VelocImmune. This antibody binds to Delta-like ligand-4 (Dll4) and will be evaluated for the treatment of solid tumors in a Phase 1 study scheduled to begin shortly.
About
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron’s web site at www.regeneron.com
Forward Looking Statement
This news release discusses historical information and includes
forward-looking statements about Regeneron and its products, development
programs, finances, and business, all of which involve a number of risks
and uncertainties, such as risks associated with preclinical and
clinical development of Regeneron’s drug candidates, determinations by
regulatory and administrative governmental authorities which may delay
or restrict Regeneron’s ability to continue to develop or commercialize
its product and drug candidates, competing drugs that are superior to
Regeneron’s product and drug candidates, uncertainty of market
acceptance of Regeneron’s product and drug candidates, unanticipated
expenses, the availability and cost of capital, the costs of developing,
producing, and selling products, the potential for any collaboration
agreement, including Regeneron’s agreements with the sanofi-aventis
Group and
Source:
Regeneron Pharmaceuticals, Inc.
Peter Dworkin, 914-345-7640
Investor
Relations
peter.dworkin@regeneron.com
or
Laura
Lindsay, 914-345-7800
Media Relations
laura.lindsay@regeneron.com
or
Olga
Fleming, 212-845-5636
Media Relations
ofleming@biosector2.com